Mohamed Farid

Mohamed Farid is a Senior Brand Manager at AstraZeneca, where they oversee a diversified pharmaceutical portfolio valued over $50 million, including Pulmicort and Nexium. They are responsible for establishing RSV prevention in Egypt and have launched Synagis, a biologic prophylaxis for high-risk pediatric populations. With a background rooted in medical sales at Boehringer Ingelheim, Sanofi, and APEX Pharma, they have also transformed the NESMET HAWA Patient Support Program, enhancing patient engagement. Mohamed holds a Bachelor's degree in Pharmaceutical Sciences from Alexandria University and has completed various business strategy courses at prestigious institutions, including the University of Virginia and The Wharton School.